Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

von Rosenberg, J. E., Halabi, S., Sanford, B. L., Himelstein, A. L., Atkins, J. N., Hohl, R. J., Millard, F., Bajorin, D. F., Small, E. J.
Veröffentlicht in Ann Oncol (2008)

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

von Sparano, J.A., Gray, R.J., Makower, D.F., Pritchard, K.I., Albain, K.S., Hayes, D.F., Geyer, C.E., Dees, E.C., Perez, E.A., Olson, J.A., Zujewski, J.A., Lively, T., Badve, S.S., Saphner, T.J., Wagner, L.I., Whelan, T.J., Ellis, M.J., Paik, S., Wood, W.C., Ravdin, P., Keane, M.M., Gomez Moreno, H.L., Reddy, P.S., Goggins, T.F., Mayer, I.A., Brufsky, A.M., Toppmeyer, D.L., Kaklamani, V.G., Atkins, J.N., Berenberg, J.L., Sledge, G.W.
Veröffentlicht in N Engl J Med (2015)